Bonesupport Holding Management

Management criteria checks 4/4

Bonesupport Holding's CEO is Emil Billbäck, appointed in Mar 2018, has a tenure of 6.17 years. total yearly compensation is SEK15.18M, comprised of 41.7% salary and 58.3% bonuses, including company stock and options. directly owns 0.69% of the company’s shares, worth €8.94M. The average tenure of the management team and the board of directors is 5 years and 7.3 years respectively.

Key information

Emil Billbäck

Chief executive officer

kr15.2m

Total compensation

CEO salary percentage	41.7%
CEO tenure	6.2yrs
CEO ownership	0.7%
Management average tenure	5yrs
Board average tenure	7.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Emil Billbäck's remuneration changed compared to Bonesupport Holding's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	kr267m
Dec 31 2023	kr15m	kr6m	kr245m
Sep 30 2023	n/a	n/a	kr214m
Jun 30 2023	n/a	n/a	-kr30m
Mar 31 2023	n/a	n/a	-kr51m
Dec 31 2022	kr18m	kr5m	-kr68m
Sep 30 2022	n/a	n/a	-kr72m
Jun 30 2022	n/a	n/a	-kr71m
Mar 31 2022	n/a	n/a	-kr82m
Dec 31 2021	kr6m	kr4m	-kr86m
Sep 30 2021	n/a	n/a	-kr88m
Jun 30 2021	n/a	n/a	-kr96m
Mar 31 2021	n/a	n/a	-kr92m
Dec 31 2020	kr11m	kr6m	-kr101m
Sep 30 2020	n/a	n/a	-kr115m
Jun 30 2020	n/a	n/a	-kr127m
Mar 31 2020	n/a	n/a	-kr151m
Dec 31 2019	kr8m	kr5m	-kr161m
Sep 30 2019	n/a	n/a	-kr166m
Jun 30 2019	n/a	n/a	-kr191m
Mar 31 2019	n/a	n/a	-kr182m
Dec 31 2018	kr6m	kr4m	-kr176m

Compensation vs Market: Emil's total compensation ($USD1.40M) is about average for companies of similar size in the German market ($USD1.61M).

Compensation vs Earnings: Emil's compensation has been consistent with company performance over the past year.

CEO

Emil Billbäck (53 yo)

6.2yrs

Tenure

kr15,176,000

Compensation

Mr. Emil Billbäck has been Chief Executive Officer at BONESUPPORT HOLDING AB (publ) since March 01, 2018. Mr. Billbäck is the Chief Executive Officer of BONESUPPORT AB. He has experience in the life scienc...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Emil Billbäck	Chief Executive Officer	6.2yrs	kr15.18m	0.69% SEK 8.9m
Håkan Johansson	Chief Financial Officer	5.5yrs	kr248.00k	0.084% SEK 1.1m
Michael Mortensen	Executive Vice President of Global R&D and Operations	2.4yrs	no data	0.020% SEK 255.7k
Annelie Vikner	Executive Vice President of Global Marketing	1.3yrs	no data	0.022% SEK 284.8k
Helena Brandt	Executive Vice President of Human Resources	6.6yrs	no data	0.030% SEK 393.4k
Michael Diefenbeck	Executive VP of Medical & Clinical Affairs and Chief Medical Officer	7.1yrs	no data	0.14% SEK 1.8m
Fergus MacLeod	GM & Executive VP of Commercial Operations of EUROW	4.5yrs	no data	0.036% SEK 471.0k
Michael Roth	GM & Executive VP of Commercial Operations of North America	3.9yrs	no data	0.030% SEK 393.4k

5.0yrs

Average Tenure

53yo

Average Age

Experienced Management: 2B4's management team is seasoned and experienced (5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Björn Odlander	Director	14.3yrs	kr302.00k	no data
Lennart Johansson	Independent Chairman of the Board	7.3yrs	kr2.94m	0.16% SEK 2.1m
Sven Bjorklund	Independent Director	7.4yrs	kr253.00k	1.56% SEK 20.1m
Christine Rankin	Independent Director	2yrs	kr756.00k	0.0030% SEK 38.7k
Mary O'Connor	Independent Director	2yrs	kr515.00k	0.038% SEK 488.7k

7.3yrs

Average Tenure

66yo

Average Age

Experienced Board: 2B4's board of directors are considered experienced (7.3 years average tenure).

Bonesupport Holding Management

Management criteria checks 4/4

Key information

Recent management updates

Bonesupport Holding AB (Publ) Announces Resignation of Kristina Ingvar as Executive Vice President Quality Management & Regulatory Affairs

Independent Director recently bought €91k worth of stock

Insider recently sold €62k worth of stock

Chief Executive Officer recently sold €1.3m worth of stock

Insider recently sold €120k worth of stock

Bonesupport Holding AB (publ), Annual General Meeting, Nov 21, 2023

Recent updates

First quarter 2024 earnings released

Full year 2023 earnings released: EPS: kr3.77 (vs kr1.06 loss in FY 2022)

Bonesupport Holding AB (Publ) Announces Resignation of Kristina Ingvar as Executive Vice President Quality Management & Regulatory Affairs

Full year 2023 earnings released: EPS: kr3.77 (vs kr1.06 loss in FY 2022)

Bonesupport Holding AB Provides Sales Guidance for the Year 2024

Investor sentiment improves as stock rises 28%

Third quarter 2023 earnings released

Bonesupport Holding AB (publ) to Report Q1, 2024 Results on Apr 25, 2024

New minor risk - Share price stability

Bone Support Receives “Breakthrough Device Designation” for Cerament® V for the Indication of Bone Infection

Independent Director recently bought €91k worth of stock

Second quarter 2023 earnings released: EPS: kr0.08 (vs kr0.25 loss in 2Q 2022)

BONESUPPORT Holding AB Announces Strong Long-Term Results with CERAMENT®G for Severe Open Fractures

Insider recently sold €62k worth of stock

Forecast breakeven date moved forward to 2023

Chief Executive Officer recently sold €1.3m worth of stock

Full year 2022 earnings released: kr1.06 loss per share (vs kr1.34 loss in FY 2021)

Insider recently sold €120k worth of stock

Full year 2022 earnings released: kr1.06 loss per share (vs kr1.34 loss in FY 2021)

Bonesupport Holding AB (publ), Annual General Meeting, Nov 21, 2023

No independent directors

Bonesupport Holding AB (publ) to Report Q3, 2023 Results on Oct 26, 2023

Third quarter 2022 earnings released

No longer forecast to breakeven

Bonesupport's CERAMENT G Used in First U.S. Patient Cases

An unknown buyer acquired unknown minority stakes in Bonesupport Holding AB (publ) (OM:BONEX) from Helena Brandt for SEK 0.84 million.

Bonesupport Holding AB (publ) Announces Publication of Mid- to Long-Term Data Confirming the Sustained Clinical Effectiveness of CERAMENT G

Second quarter 2022 earnings released: kr0.25 loss per share (vs kr0.42 loss in 2Q 2021)

Forecast breakeven date moved forward to 2023

BONESUPPORT Receives Market Authorization for CERAMENT G in the US

Forecast breakeven date pushed back to 2024

Chairman of the Board recently bought €117k worth of stock

Forecast breakeven date pushed back to 2024

Less than half of directors are independent

Full year 2021 earnings released: kr1.34 loss per share (vs kr1.72 loss in FY 2020)

Bonesupport Holding AB (publ) to Report Fiscal Year 2021 Final Results on Apr 13, 2022

BONESUPPORT(TM) Announces Delays Within FDA Postpones CERAMENT G De Novo Decision

Forecast breakeven date pushed back to 2024

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Executive Vice President of Manufacturing & Supply Johan Olsson has left the company

Executive VP of Medical & Clinical Affairs and Chief Medical Officer Michael Diefenbeck has left the company

Third quarter 2021 earnings released

Bonesupport Announces Supplementary US Denovo Application Submitted

Forecast to breakeven in 2023

Bonesupport Announces Study Results for its Investigational Device Exemption(IDE) Study, Fortify

Forecast to breakeven in 2023

Chief Financial Officer recently bought €8.5k worth of stock

Executive VP of R&D recently sold €59k worth of stock

Chairman of the board recently bought €157k worth of stock

Second quarter 2021 earnings released

No longer forecast to breakeven

BONESUPPORTTM Receives Device Designation for CERAMENT G for the Indication Trauma

Forecast to breakeven in 2023

First quarter 2021 earnings released

Full year 2020 earnings released: kr1.72 loss per share (vs kr3.10 loss in FY 2019)

Chief Executive Officer recently bought €40k worth of stock

New 90-day low: €5.70

Bonesupport Holding AB (publ) Receives Notification from the US Food and Drug Administration

Full year 2020 earnings released: kr1.72 loss per share (vs kr3.10 loss in FY 2019)

Revenue beats expectations

Executive VP of R&D recently bought €6.8k worth of stock

New 90-day high: €7.40

Bonesupport Holding AB (Publ) Announces Resignation of Simon Cartmell from the Board of Directors

Revenue beats expectations

Third quarter 2020 earnings released: kr0.33 loss per share

Bonesupport Holding AB (publ) to Report First Half, 2021 Results on Jul 15, 2021

New 90-day high: €6.70

New 90-day high: €6.52

New 90-day high: €6.48